Banfi G, Bravi S, Ardemagni A, Zerbi A
Servizio Integrato di Medicina di Laboratorio, Istituto Scientifico H. S. Raffaele, Milano, Italy.
Int J Biol Markers. 1996 Apr-Jun;11(2):77-81. doi: 10.1177/172460089601100203.
The diagnosis of pancreatic cancer is usually made in the advanced stages of the disease when the prognosis is poor. We compared the behavior of CA19.9, CEA and the newly proposed mucin CA242 in a consecutive series of 42 pancreatic carcinomas. A control group was recruited of 21 patients with benign pancreatic diseases. With the recommended cutoffs (37 U/ml for CA19.9, 20 U/ml for CA242 and 8 ng/ml for CEA) we obtained a specificity of 90% for CA19.9 and of 85% for CA242 and CEA. The sensitivity was 85.7% for CA19.9, 73.8% for CA242 and 26.2% for CEA. CA19.9 and CA242 showed identical behavior in various TNM stages of cancer and in stages III and IV of the Hermreck classification. Moreover, CA19.9 and CA242 showed identical behavior in 10 patients monitored during the survival period who developed recurrence of disease. ROC curve evaluation demonstrated that CA242 and CA19.9 were very similar. The results of CA242 were better than those of CA19.9 in the false positive range under 10%, whereas CA19.9 had a better performance in the true positive range over 70%. CA242 could be used instead of CA19.9 for diagnosing pancreatic carcinoma.
胰腺癌通常在疾病晚期才得以诊断，此时预后较差。我们在连续的42例胰腺癌病例中比较了CA19.9、癌胚抗原（CEA）以及新提出的粘蛋白CA242的表现。招募了一个由21例胰腺良性疾病患者组成的对照组。采用推荐的临界值（CA19.9为37 U/ml，CA242为20 U/ml，CEA为8 ng/ml），我们得出CA19.9的特异性为90%，CA242和CEA的特异性为85%。CA19.9的敏感性为85.7%，CA242为73.8%，CEA为26.2%。在癌症的各个TNM分期以及Hermreck分类的III期和IV期，CA19.9和CA242表现出相同的行为。此外，在生存期接受监测且出现疾病复发的10例患者中，CA19.9和CA242也表现出相同的行为。ROC曲线评估表明，CA242和CA19.9非常相似。在假阳性率低于10%的范围内，CA242的结果优于CA19.9，而在真阳性率超过70%的范围内，CA19.9表现更佳。CA242可替代CA19.9用于诊断胰腺癌。
